US Patent 9,029,416: Scope, Claims, Expiration, Orange Book Status and Generic Entry Risk

US Patent 9,029,416, titled “Osmotic Dosage Forms with Ascending Release Rates,” protects multipart osmotic oral dosage forms that deliver CNS stimulants, particularly methylphenidate hydrochloride, through a semipermeable membrane and laser-drilled or mechanically formed passageway. Its strongest commercial relevance is to OROS-style extended-release methylphenidate products, including Concerta-related formulations.

The patent does not claim methylphenidate as a chemical compound. It claims a delivery architecture: layered tablet cores, expandable push layers, osmotic membranes, drug-release passageways, immediate-release coatings, and ascending or programmed release profiles.

What does US Patent 9,029,416 protect?

The patent has four principal claim groups:

Claim group	Claims	Subject matter	Primary risk target
Osmotic dosage form	1-10	Capsule-shaped, multilayer osmotic tablet for specified CNS stimulants	Product formulation
Three-layer ascending-release dosage form	11-21	Low-dose drug layer, higher-dose drug layer, expandable third layer and ascending release	Product formulation and release profile
Two-layer methylphenidate dosage form	22-33	Methylphenidate drug layer, fluid-expanding layer, semipermeable membrane and adjacent orifice	Concerta-type product
Oral-use and release-profile claims	34-46	Administration methods and progressively increasing release across timed intervals	Method of use and performance characteristics

The patent is directed to drug products in which fluid enters through a semipermeable membrane, hydrates an osmotic or expandable layer, and displaces the drug-containing layer toward an exit passageway. The release mechanism is controlled by the interaction of:

The membrane's permeability.
The composition and expansion rate of the push layer.
The location and dimensions of the orifice.
The drug-layer arrangement.
The amount and concentration of drug in each layer.
The immediate-release coating, if present.

The patent therefore creates both structural and functional infringement theories.

How many independent claims does US 9,029,416 have?

The patent contains at least eight commercially important independent claim categories, although the precise claim dependency structure must be read from the issued patent certificate and any subsequent correction or disclaimer record.

The principal independent claims are:

Claim 1: A multilayer osmotic dosage form containing a specified CNS stimulant.
Claim 11: A three-layer dosage form with sequential drug-layer displacement and ascending release.
Claim 22: A two-layer methylphenidate dosage form with an adjacent orifice.
Claim 34: Oral administration of the claim 1-type methylphenidate dosage form.
Claim 35: Oral administration of the three-layer ascending-release dosage form.
Claim 36: Oral administration of the two-layer methylphenidate dosage form.
Claim 37: A two-layer methylphenidate dosage form with increasing release over sequential intervals.

Claims 38-46 narrow claim 37 by adding further release intervals, immediate-release coating, time intervals, oral administration, and a third drug-containing layer.

The broadest product claims are claims 1, 11, 22 and 37. Claims 34-36 create corresponding method-of-use exposure for oral administration.

What are the key limitations in claim 1?

Claim 1 requires all of the following elements:

Limitation	Required feature
Dosage form	Osmotic dosage form
Core geometry	Capsule-shaped longitudinally compressed tablet core
Core structure	Plurality of layers
Drug	CNS stimulant selected from methylphenidate, d-threo-methylphenidate, amphetamine, dextroamphetamine, methamphetamine or pemoline
Expandable component	At least one layer containing a fluid-expandable polymer
Wall	Semipermeable wall surrounding the core
Osmosis	Wall and core form a compartment with an osmotic gradient
Passageway	Orifice through the wall and into the core
Function	Passageway permits drug release into the external fluid environment

The claim does not require methylphenidate specifically. It covers the listed stimulant class. Claims 6 and 12, among others, narrow the scope to methylphenidate or methylphenidate hydrochloride.

A competing product could avoid claim 1 by omitting a listed stimulant, using a non-osmotic release mechanism, using a non-expandable matrix, or adopting a dosage form that does not have the required capsule-shaped longitudinally compressed core. Avoiding one element is sufficient to avoid literal infringement, subject to potential doctrine-of-equivalents issues.

What do claims 11 through 21 protect?

Claims 11-21 protect a more technically defined three-layer system:

A first drug layer.
A second drug layer containing more drug than the first layer.
A third expandable layer that displaces the first drug layer followed by the second drug layer.
A wall permeable to fluid but impermeable to drug.
A passageway communicating with the first drug layer.
An ascending release rate beginning at administration and continuing for at least approximately 5.5 hours.

The claim is important because it combines composition and release behavior. A product may have the required layers but still avoid infringement if it does not produce the claimed ascending release profile. Conversely, a product with an ascending profile may avoid the claim if its drug layers are not arranged in the claimed concentration order.

Dependent claims add:

Methylphenidate hydrochloride.
A drug-layer overcoat.
An osmagent in the expandable layer.
At least about 35% osmagent.
Sodium chloride as the osmagent.
An immediate-release drug coating.
Phosphoric acid as an antidegradation agent.
Cellulose acetate membrane.
Ethylene oxide/propylene oxide copolymer as a flux enhancer.

These limitations provide narrower but potentially stronger positions against products that reproduce the disclosed OROS formulation.

What do claims 22 through 33 protect?

Claims 22-33 are directed to a two-layer methylphenidate dosage form. The required architecture is:

A capsule-shaped tablet core.
A first layer containing methylphenidate or a pharmaceutically acceptable salt.
A second adjacent layer containing a fluid-expanding polymer.
A semipermeable membrane.
An osmotic gradient.
An orifice adjacent to the methylphenidate layer.
Ascending release for at least approximately 5.5 hours.

The dependent claims cover:

Claim	Added limitation
23	100 ng to 500 mg of methylphenidate
24	Drug-layer overcoat
25	Osmagent in the second layer
26	Bi-layer drug/push-layer configuration
27	At least about 35% osmagent in the push layer
28	Sodium chloride osmagent
29	Immediate-release methylphenidate coating
30	Antidegradation agent
31	Phosphoric acid
32	Cellulose acetate and flux enhancer
33	Ethylene oxide/propylene oxide copolymer

Claim 22 is commercially significant because it does not require the three-layer arrangement of claim 11. A two-layer OROS methylphenidate product can fall within the claim if it has the specified core geometry, membrane, orifice location and ascending release behavior.

What release profile does claim 37 require?

Claim 37 requires progressively increasing release across at least three sequential equal-duration intervals:

More drug is released during the second interval than during the first.
More drug is released during the third interval than during the second.

Claim 38 extends the progression to a fourth interval. Claims 41 and 42 define the intervals as 30 minutes or one hour. Claims 43 and 44 exclude drug released from the immediate-release coating when measuring release from the capsule-shaped core during the first interval.

This creates a performance-based limitation. In an infringement dispute, dissolution testing would likely be central. Relevant evidence could include:

USP dissolution profiles.
Release-rate calculations.
Sampling intervals.
Treatment of the immediate-release coating.
Lot-to-lot variability.
The definition of “more drug.”
Whether the comparison concerns absolute quantity or rate normalized for interval duration.

The claim language is vulnerable to disputes over test conditions and statistical significance, especially where the product's release curve is approximately ascending but contains plateaus or manufacturing variability.

What formulation patents are related to Concerta and OROS methylphenidate?

US 9,029,416 belongs to the broader Alza/Janssen OROS methylphenidate patent estate. The relevant portfolio generally includes patents covering:

Technology area	Typical protected subject matter
Core OROS architecture	Drug layer, push layer, semipermeable membrane and passageway
Methylphenidate formulations	Methylphenidate hydrochloride, dose loading and release profile
Immediate-release overcoat	Initial bolus followed by controlled osmotic delivery
Ascending release	Increasing delivery rate over defined time periods
Membrane chemistry	Cellulose acetate and permeability modifiers
Push-layer composition	Polymeric expansion systems and sodium chloride
Manufacturing	Compression, coating, drilling and assembly of osmotic tablets
Product-specific performance	Dissolution and pharmacokinetic characteristics

Earlier Concerta-related patents, including US 5,837,284 and US 6,919,373, addressed OROS methylphenidate technology and were involved in historical generic litigation. US 9,029,416 is part of the later continuation and improvement landscape rather than a patent on methylphenidate itself. [1-4]

When does US 9,029,416 lose exclusivity?

The patent term is governed by the earliest effective nonprovisional priority date in the relevant family, plus any patent term adjustment. A patent's issue date does not establish its expiration date.

The enforceability analysis should include:

Term issue	Relevance
Earliest nonprovisional filing date	Establishes the ordinary 20-year term
Continuation status	Usually does not restart patent term
Patent term adjustment	Can extend the nominal term
Patent term extension	Generally uncommon for formulation patents unless statutory requirements are met
Terminal disclaimer	Can shorten the term if required by obviousness-type double patenting
Maintenance fees	Nonpayment can cause expiration, subject to revival rules
Disclaimer or reexamination	Can narrow or eliminate claims

The operative expiration date should be taken from the USPTO Patent Center record and the current Orange Book patent table, rather than inferred solely from the 2015 issue date. [2, 5]

Is US 9,029,416 listed in the Orange Book?

Orange Book listing is product-specific. A patent may be technically relevant to a methylphenidate product without being listed against every methylphenidate product.

The key regulatory questions are:

Whether the patent is listed against Concerta or another FDA-approved extended-release methylphenidate product.
Whether the listing covers the drug substance, drug product, or method of use.
Whether the listed claims correspond to the approved formulation.
Whether the patent was timely submitted for listing.
Whether the patent has been delisted, expired or removed.
Whether an ANDA applicant must certify under Paragraph IV.

The FDA Orange Book, not the patent specification, determines the practical effect of an Orange Book listing. A listed formulation or method-of-use patent can trigger a Paragraph IV notice and a 30-month stay if the statutory requirements are satisfied. [2]

What Paragraph IV challenges and litigation affect this patent estate?

The major generic litigation history for Concerta involved Teva, Actavis and other generic applicants challenging earlier Alza/Janssen patents. The disputes focused on whether generic extended-release methylphenidate products reproduced the patented OROS release pattern and whether their dissolution profiles were equivalent.

The principal litigation issues in this product class have included:

Infringement of OROS structural claims.
Validity of claims covering ascending release.
Obviousness based on earlier osmotic pump patents.
Written description and enablement of release-rate limitations.
The effect of product-specific dissolution data.
FDA determination of therapeutic equivalence.
Launch risk after Paragraph IV certification.
Settlement timing and authorized-generic exposure.

A Paragraph IV challenge to US 9,029,416 would likely focus on claim construction and invalidity rather than the methylphenidate molecule. Potential defenses could include:

The accused product lacks a capsule-shaped longitudinally compressed core.
The membrane does not have the claimed permeability or flux-enhancing composition.
The orifice is not adjacent to the claimed drug layer.
The product does not contain the required expandable polymer or osmagent.
The release profile is not ascending for the claimed duration.
The claims are obvious over earlier osmotic dosage-form references.
The claims lack written-description support for the full stimulant or dosage range.

How strong is the patent estate for generic entry analysis?

The estate is strongest where a product copies the complete OROS architecture. Structural claims can be more predictable to enforce than claims based only on dissolution behavior.

Risk factor	Assessment
Chemical-entity protection	Low; the patent does not claim methylphenidate itself
Core-device protection	High for products using the claimed layered osmotic architecture
Release-profile protection	Moderate to high, but testing and claim construction are critical
Immediate-release coating protection	Moderate; dependent claims narrow the scope
Membrane-composition protection	Moderate; formulation records are needed
Manufacturing protection	Potentially significant if production reproduces the claimed structure
Biosimilar exposure	None; methylphenidate is a small molecule
Design-around potential	Moderate, if a competitor uses a non-osmotic or materially different system
Litigation leverage	Highest before patent expiration and where Orange Book listed
Post-expiration value	Primarily know-how, trade secrets and manufacturing capability

The patent does not create biosimilar risk because methylphenidate is a chemically synthesized small molecule. Competitive entry proceeds through the ANDA pathway, not the biosimilar BLA pathway.

What generic launch scenarios exist?

At-risk launch before patent expiry

A generic applicant may launch after receiving FDA approval but before resolution of patent litigation. This creates damages exposure and potential injunctive relief. The risk is highest where the applicant has certified Paragraph IV against an unexpired listed patent.

Launch after settlement date

A settlement may permit entry before the patent's statutory expiration. The commercial outcome depends on:

Entry date.
Authorized generic rights.
Supply obligations.
Restrictions on formulation changes.
Patent challenge covenants.
Allocation of launch volume.
Treatment of future continuation patents.

Launch after expiration

This is the lowest patent-infringement risk scenario, but formulation patents in the same family, later continuations, regulatory exclusivity and manufacturing patents still require review.

Non-infringing design-around

A competitor could use:

A conventional matrix tablet.
A multiparticulate bead system.
A coated pellet system.
A different osmotic architecture.
A non-capsule-shaped core.
A membrane and push-layer composition outside the dependent claims.
A release profile that is controlled but not progressively ascending.

A design-around must be evaluated against every independent claim, not only claim 22 or claim 37.

How does US 9,029,416 compare with earlier OROS patents?

Issue	Earlier OROS patents	US 9,029,416
Primary focus	General osmotic systems and methylphenidate delivery	Specific layered cores and ascending release
Chemical protection	Generally absent or limited	Absent
Device structure	Broad osmotic architecture	Capsule-shaped, longitudinally compressed multilayer core
Release profile	Controlled or sustained release	Ascending release over defined intervals
Coating claims	May cover immediate-release dose	Expressly covers drug coating and phosphoric acid
Membrane claims	Broad membrane and flux concepts	Cellulose acetate and ethylene/propylene oxide copolymer
Generic vulnerability	Prior-art and obviousness challenges	Functional-release and structural design-around issues

The patent's commercial value depends on whether the approved product and the generic product use the claimed architecture. It does not block all extended-release methylphenidate products.

What is the geographic scope of US 9,029,416?

US 9,029,416 has territorial effect only in the United States. Foreign family members must be reviewed separately in:

Canada.
Europe and validated European countries.
Japan.
Australia.
China.
South Korea.
Other markets where OROS methylphenidate products are sold.

The foreign portfolio may have different claims, prosecution histories, expiration dates, annuity status and litigation outcomes. A US freedom-to-operate opinion does not establish clearance in other jurisdictions.

What manufacturing and IP barriers remain after patent expiration?

Even after patent expiry, a competitor may face practical barriers:

High-precision multilayer compression.
Uniform membrane coating.
Reliable orifice formation.
Control of osmotic expansion.
Stability of methylphenidate under coating conditions.
Reproducible ascending dissolution.
Scale-up of push-layer composition.
FDA bioequivalence and product-specific guidance.
Controlled-substance manufacturing and distribution requirements.

These barriers are not equivalent to patent exclusivity. They may delay launch but do not independently prevent competition.

Key Takeaways

US 9,029,416 protects OROS-style, multilayer osmotic dosage forms rather than methylphenidate as a molecule.
Claims 1, 11, 22 and 37 are the principal commercial claims.
The core limitations are a capsule-shaped layered tablet, expandable push layer, semipermeable membrane, internal orifice and ascending release.
Claims 22-33 are especially relevant to two-layer methylphenidate products.
Claims 37-46 create dissolution and timed-interval exposure based on progressively increasing release.
Immediate-release coatings, phosphoric acid, sodium chloride, cellulose acetate and ethylene oxide/propylene oxide copolymer are narrower dependent-claim features.
Biosimilar law is irrelevant because methylphenidate is a small molecule.
Paragraph IV risk depends on Orange Book listing, remaining patent term and the applicant's formulation.
A conventional non-osmotic extended-release product may avoid the patent, but a copied OROS architecture presents substantially greater infringement risk.
Patent expiration, terminal disclaimer status, maintenance fees and Orange Book listing must be assessed from current USPTO and FDA records.

FAQs About US Patent 9,029,416

Does US 9,029,416 cover all extended-release methylphenidate products?

No. It covers products with specific osmotic, multilayer and release-profile characteristics. Matrix tablets, beads, coated particles and other non-osmotic systems may fall outside its claims.

Does a generic Concerta product automatically infringe US 9,029,416?

No. Infringement depends on the generic's actual formulation, manufacturing process and release profile. FDA therapeutic equivalence does not itself establish patent infringement.

Can a generic avoid the patent by removing the immediate-release coating?

Potentially, but removing the coating does not avoid claims that do not require an immediate-release coating. Claims 1, 11, 22 and 37 must be analyzed independently.

Does the patent protect the OROS trademark or Concerta brand?

No. Patent protection and trademark protection are separate. US 9,029,416 concerns dosage-form technology, not the Concerta name.

Are foreign patents equivalent to US 9,029,416?

Not necessarily. Foreign family members may have different claim scope, expiration dates and legal status. Each jurisdiction requires a separate patent and prosecution-history analysis.

References

United States Patent and Trademark Office. (2015). U.S. Patent No. 9,029,416, Osmotic dosage forms with ascending release rates.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
United States Patent and Trademark Office. (2024). Patent Center: U.S. Patent No. 9,029,416 prosecution and maintenance records.
United States Court of Appeals for the Federal Circuit. (2010). In re Omeprazole Patent Litigation, 536 F.3d 1361.
United States Code, Title 35, §§ 154 and 156. (2024). Patent term and patent term extension provisions.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	277594	⤷ Start Trial
Austria	321529	⤷ Start Trial
Austria	325606	⤷ Start Trial
Australia	4319799	⤷ Start Trial
Australia	4801497	⤷ Start Trial
Australia	5267698	⤷ Start Trial
Australia	9639101	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,029,416

Summary for Patent: 9,029,416